Telix Pharmaceuticals Limited Announces Unaudited Revenue Results for the Fourth Quarter and Full Fiscal Year 2023
The total revenue (unaudited) for Fiscal Year 2023 is $502.5 million (USD 333.0 million).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.91 AUD | +0.20% | +9.55% | +47.92% |
1st Jan change | Capi. | |
---|---|---|
+47.92% | 3.21B | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |